View Author
patient group cancer study survival treatment leukemia myeloid leukemia analysis mutation table prognostic cytogenetic expression breast result breast cancer factor myeloid chemotherapy therapy prostate cancer blood abnormality value trial cycle month number signi remission evi 1 tumor prostate status grade donor outcome effect difference lymphoma university response level radiotherapy platelet sample disease model transfusion erasmu karyotype evi 1 expression score radiation oncol methylation square meter center death relapse ratio g-csf figure induction ficant author prognosis adjuvant 1-evi transplantation hospital event chromosome event-free survival women j clin oncol manuscript erasmus university cluster
10 Most Recent Publications
|
Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers
(Article)
Rockova, V. Abbas, S. Wouters, B.J. Erpelinck, C.A.J. Beverloo, H.B. Delwel, H.R. Putten, W.L.J. van Löwenberg, B. Valk, P.J.M. |
2011-07-28
|
|
Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
(Article)
Kluin-Nelemans, H.C. Marwijk Kooy, M. van Lugtenburg, P.J. Putten, W.L.J. van Luten, M. Oudejans, J. Imhoff, G. van |
2011-07-04
|
|
Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: Long-term results of the dutch randomized dose-escalation trial (CKTO 96-10 Trial)
(Article)
Al-Mamgani, A. Putten, W.L.J. van Wielen, G.J. van der Levendag, P.C. Incrocci, L. |
2011-03-15
|
|
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction
(Article)
Kerkhoffs, J.-L.H. Putten, W.L.J. van Brand, A. Rhenen, D.J. van Novotny, V.M.J. Boekhorst, P.A.W. te Schipperus, M.R. Zwaginga, J.J. Pampus, L.C.M. Greef, G.E. de Luten, M. Huijgens, P.C. |
2010-07-01
|
|
Gemtuzumab ozogamicin as postremission treatment inAMLat 60 years of age or more: results of a multicenter phase 3 study
(Article)
Löwenberg, B. Beck, J.A. Biemond, B.J. Vellenga, E. Breems, D.A. Muijnck, H. de Schaafsma, R. Verhoef, G. Döhner, H. Gratwohl, A. Pabst, T. Ossenkoppele, G.J. Graux, C. Maertens, J. Putten, W.L.J. van Schouten, H.C. Verdonck, L.F. Ferrant, A. Sonneveld, P. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2010-04-01
|
|
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
(Article)
Nout, R.A. Smit, V.T.H.B.M. Bunningen, B.N.F.M. van Ansink, A.C. Putten, W.L.J. van Creutzberg, C.L. Putter, H. Jürgenliemk-Schulz, I.M. Jobsen, J.J. Lutgens, L.C.H.W. Steen-Banasik, E.M. van der Mens, J.W.M. Slot, A. Kroese, M.S. |
2010-03-08
|
|
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
(Article)
Figueroa, M.E. Lugthart, S. Campagne, F. Mazumdar, M. Greally, J.M. Valk, P.J.M. Löwenberg, B. Delwel, H.R. Melnick, A. Li, Y. Erpelinck, C.A.J. Deng, X. Christos, P.J. Schifano, E. Booth, J. Putten, W.L.J. van Skrabanek, L. |
2010-01-19
|
|
High-dose daunorubicin in older patients with acute myeloid leukemia
(Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2009-09-24
|
|
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
(Article)
Wouters, B.J. Löwenberg, B. Erpelinck, C.A.J. Putten, W.L.J. van Valk, P.J.M. Delwel, H.R. |
2009-03-26
|
|
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
(Article)
Veer, M.B. van 't Jong, D. de MacKenzie, M. Kluin-Nelemans, H.C. Oers, M.H.J. van Zijlstra, J. Hagenbeek, A. Putten, W.L.J. van |
2009-02-01
|
